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The use of anti-idiotype antibodies as vac-
cines to stimulate antitumor immunity is 
a very promising pathway in the therapy 
of cancer. A good body of work in ani-
mal tumor models have demonstrated the 
efficacy of anti-Id vaccines in preventing 
tumor growth and curing mice with estab-
lished tumors. A number of monoclonal 
anti-Id antibodies that mimic different 
human tumor-associated antigens (TAAs) 
have been developed and tested in the 
clinic, demonstrating interesting. In gen-
eral terms, the antigen mimicry by anti-Id 
antibodies has reflected structural homol-
ogy in the most of the cases, and amino acid 
sequence homology in a minority of them. 
The major challenge of immunotherapy 
using  anti-idiotype vaccines is to identify 
the optimal anti-idiotype antibody that will 
function as a true surrogate antigen for a 
TAA system, and ideally will generate both 
humoral and cellular immune responses. 
Several clinical studies have shown enhanced 
patient’s survival when receiving anti-Id vac-
cines, the true demonstration of efficacy of 
these vaccines will depend upon the results 
of several randomized Phase III clinical tri-
als that are currently planned or ongoing 
(Bhattacharya-Chatterjee et al., 2002).
With the numerous antigens that can be 
used in immunotherapy the decision making 
process for researchers, hospitals, and com-
panies, in whether or not invest resources in a 
specific antigen has been always a very com-
plicated matter both for classic therapeutic 
vaccines and even more for anti-idiotype 
vaccines. Fortunately, in a recent work by 
the National Cancer Institute Translational 
Research Working Group (Cheever et al., 
2009) was developed a method for prioriti-
zation of cancer antigens paving the way to 
take more rational, informed decisions. Such 
work aimed to develop a priority-ranked 
list of cancer vaccine target antigens based 
on predefined and preweigthed objective 
criteria. An additional aim was testing a 
new approach for prioritizing translational 
research opportunities based on an analytic 
hierarchy process (AHP), a structured tech-
nique and mathematical model for dealing 
with complex decisions. Antigen prioriti-
zation involved developing a list of “ideal” 
cancer antigen criteria/characteristics, 
assigning relative weights to those criteria 
using pairwise comparisons. The result of 
the criteria weighting, in descending order, 
was as follows: (a) therapeutic function, (b) 
immunogenicity, (c) role of the antigen in 
oncogenicity, (d) specificity, (e) expression 
level and percent of antigen-positive cells, (f) 
stem cell expression, (g) number of patients 
with antigen-positive cancers, (h) number of 
antigen epitopes, and (i) cellular location of 
antigen expression.
Some authors have enunciated the intro-
duction of potential biases in the National 
Cancer Institute Pilot Project (Lang et al., 
2009). These authors affirmed that the meth-
odology used (AHP), is not well described, 
and is subject to several sources of possible 
bias, such as participant selection, number of 
antigens chosen for prioritization, errors in 
rank order, redundancy, and internal validity. 
First of all, we differ with Lang et al. in the 
fact that AHP is not well described, beyond 
being a very well known technique properly 
used in a variety of settings, including can-
cer clinical decisions (Katsumura et al., 2008; 
see also Dolan and Iadarola, 2008). Cheever 
et al. clearly described the method by citing 
the popular work of Busham and Rai (2004) 
and how AHP is used in a Web-based tool 
(Olson et al., 2007). AHP is a powerful tool, 
used widely in science, and although has had 
some detractors over the years, Forman and 
Gass (2010) carried out an in-depth paper 
discussing and rebutting the academic criti-
cisms of AHP.
Anti-idiotype cancer vaccines develop-
ment is limited by several factors, includ-
ing funding concerns. The work of Cheever 
et al. in our opinion can also be used as a 
map to develop stronger and faster evidence 
or in case of failure, deciding when to stop a 
project. The associated lists of weighted cri-
teria enumerated in Cheever’s paper inform 
investigators as to what experimental evi-
dence is required to advance antigens to 
higher priority levels, therefore, improving 
its chance to pass to translational research. 
Also, the lack of superb data, especially in 
the therapeutic function, could be multi-
factorial, including inadequate trial design 
or patient selection and inadequate vaccine 
formulation or regimens. These deficiencies 
can be overcome by more intelligent trial 
design based on assessment of past “pro-
ductive failures.”
Having that work as a reference, we ana-
lyzed the data available for the anti-idiotype 
vaccine Racotumomab (formerly known 
as 1E10) and its target antigen, N-glycolyl 
(NGc)-containing gangliosides and par-
ticularly NGcGM3 (reviewed in detail by 
Fernandez et al., 2010). As shown in Table 1, 
the antigen match all criteria considered at 
least in some proportion, having a cumu-
lative score of 0.62. Interestingly, with this 
score NGcGM3 ranked within the top 15th 
cancer antigens selected by Cheever et al., 
with a score similar to the GD2 ganglioside, 
the Melan A/MART1 gene product, or the 
carcinoembrionic antigen.
At the time of Cheever’s publication no 
cancer vaccine was yet approved by FDA. 
However, recent approval of sipeleucel-T 
for men with advanced prostate cancer tar-
geting PAP antigen, gave us a valuable les-
son on this matter (Bot, 2010). Interestingly, 
PAP ranked 26 out of 75 antigens in the 
ranking of cancer antigen pilot prioritiza-
tion, confirming its capacity to somehow 
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“forecast” those antigens more likely to be 
translated to patients. Although the rank-
ing is dynamic, given that priorities change 
as knowledge accrues from new studies, we 
must reinforce the idea that the associated 
lists of weighted criteria inform investiga-
tors as to what experimental evidence is 
required to advance antigens to higher pri-
ority levels, and even more, if the antigen of 
choice is relevant. Always perfectible, those 
criteria helped us to evaluate that NGcGM3 
comprised most if not all the criteria. 
Therefore NGc-containing gangliosides are 
antigens worth investing in the acceleration 
of its translational research.
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Table 1 | Relevant characteristics and score for NGcGM3 ganglioside as a cancer antigen, according to the antigen prioritization criteria described by 
Cheever et al. (2009).
Criteria Subcriteria for NGcGM3 Score (total weight 
of criteria)
Therapeutic function Adequate data, controlled vaccine trial suggestive 0.27 (0.32)
Immunogenicity T-cell and antibody responses elicited in clinical trials 0.17 (0.17)
Oncogenicity Increased expression correlated with survival and advanced disease, but oncogenic 
function need to be clarified
0.03 (0.15)
Specificity Overexpressed in cancer with little or no expression in normal adult tissues 0.05 (0.15)
Expression level and% positive cells Highly expressed on most cancer cells in patients designated for treatment 0.02 (0.07)
Stem cell expression Expression on most cancer cells but without information about putative stem cells 0.01 (0.05)
No. patients with antigen-positive cancers High level of expression in many patients with a particular tumor type 0.04 (0.04)
No. antigen epitopes Short antigenic segment with one or few epitopes 0.01 (0.04)
Cellular location of antigen expression Expressed on the cell surface with little or no circulating antigen 0.02 (0.02)
Cumulative score for NGcGM3 0.62 (1.00)
